3rd ESTRO Forum 2015 S343 patients with inoperable HCC (N=30) received single transarterial chemoembolization (TACE) followed by volumetricmodulated arc radiotherapy (VMAT)-based SBRT applying the van Herk margin recipe with mid-ventilation concept. Doses of SBRT were individualized according to normal tissue constraints. Tumor localization was performed by 4D CBCT using lipiodol as surrogate. Tumor responses were assessed by CT images using RECIST criteria every 3 months in the first year. In-field recurrence was defined as recurrence within the high-dose region (80% isodose volume). Overall survival, progression-free survival and local control rates were evaluated by the Kaplan-Meier method. Toxicities were graded according to CTCAE version 4. Results: Median follow-up time was 12 months (range: 4.2-30.6 months). Patients' characteristics were as follows: Median age (61 years, range: 28-87); Male/ female (n= 28/2); Child-Pugh class A/B (n= 28/2); ECOG 0-1/2 (n=21/9); BCLC stage A/B/C (n= 2/14/14); TNM stage I/II/III/IV (n=10/0/17/3); Solitary/ Multifocal (n=20/10); Portal vein thrombosis (n=8). Median size of tumor was 12.7cm (range: 4.4-19.7cm) and Median GTV size was 937cc (range: 81-3218cc). Median dose (2Gy equivalent, a/b=3) was 75Gy (range: 56-140Gy). Overall objective response rate was 67% (CR: n=1, PR: n=19). The 1-year in-field control, overall survival (OS) and progression-free survival (PFS) rate was 86%, 65% and 42% respectively. Median survival not yet reached. Treatments were well tolerated. No grade 4-5 toxicities were observed. Most common grade 3 toxicities were elevation of liver enzymes (n=6, 20%) and thrombocytopenia (n=1, 3%). No patient developed radiationinduced liver disease (RILD). Conclusions: 4DCBCT guided SBRT using lipidiol as surrogate for tumor localization is feasible for inoperable HCC patients. It is safe, well tolerated and achieves high in-field control rate.
Purpose/Objective: Neo-adjuvant chemoradiotherapy (neo-CRT) followed by surgery is currently the standard curative treatment for esophageal cancer. Both modalities may cause serious toxicity and morbidity. The aim of this study was to evaluate the incidence of pleural and pericardial effusion after neo-CRT followed by surgery and to investigate the impact on quality of life (QoL). Materials and Methods: Patients, that were included in a prospective trial to evaluate the impact of PET/CT for radiotherapy planning , underwent routine CT scanning during follow up in order to evaluate tumour recurrences. All these follow up CT's were blindly reviewed by a radiologist for signs of pleural and/or pericardial effusion. The degree of these toxicities was categorized as minor, moderate or severe. QoL questionnaires (EORTC QLQ-C30) were part of this follow up as well and were used to evaluate the impact of pleural and/or pericardial effusion . To investigate the relationship between pleural or pericardial effusion and the different domains of QoL a ANOVA was used. Results: Seventy-one patients were treated with neo-CRT and underwent routine CT scanning during follow up in absence of known recurrence and insufficient physical condition. The disease free survival (DFS) was 79%, 59% and 52% at 6, 12 and 18 months after neo-CRT. At that time, 50, 42 and 35 patients underwent follow up CT's. Pleural effusion occurred in 25 patients (50%) at 6 months and reduced over time; 33% at 12 months and 31% at 18 months. The degree was minor, moderate and severe in 11, 10 and 4 patients at 6 months. At 18 months severe pleural effusion was still present in 3 patients (9%). Pericardial effusion was seen in only 3 patients (6%) and completely reduced over time; 2.4% at 12 months and 0% at 18 months. Both pleural and pericardial effusion seemed of non-malignant origin, except for one patient with progressive malignant pleural effusion. Pleural effusion had a significant impact on physical functioning (p=0.001) and significantly enhanced dyspnoea (p=0.02). The mean score for physical functioning was 69 (SD: 26.3) in patients with pleural effusion vs. 82 (SD: 14.3) in absence of pleural effusion. Furthermore, pericardial effusion was significantly related to decreased global health status (39 vs. 75, p Conclusions: Pleural effusion is frequently observed after neo-CRT followed by surgical resection and improved over time and persisted up to 18 months pleural in 31% of the patients. Pericardial effusion is less common. Both pleural and pericardial effusions have a significant impact on QoL in terms of decreased physical functioning and increased dyspnoea.
